Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gel aims to stop bleeding in kidney surgery – but study never started

NCT ID NCT07284953

Disease control Sponsor: The Royal Wolverhampton Hospitals NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study planned to test a material called PuraBond that helps stop bleeding during robotic surgery for kidney cancer. The goal was to see if it works safely and helps the kidney heal. However, the study was withdrawn before any participants were enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female patients, aged 18 years or above 2. Patient has a clinical indication for laparoscopic partial nephrectomy procedure 3. Participant is willing and able to give informed consent for participation in the study 4. Intraoperative criteria: Subject requiring the use of PuraBond for persisting mild and moderate bleeding(s) when haemostasis by ligation or standard means are insufficient or impractical. Exclusion Criteria: 1. Pregnant or Lactating women 2. Unable to give informed consent 3. Patient undergoing redo surgery 4. Fibrin glue and/or topical haemostatic agent used before or concomitantly to the use of PuraBond 5. Known allergy or hypersensitivity to any component of the investigational treatment PuraBond 6. Known coagulopathy 7. Clinical indication not satisfying inclusion criteria 8. Patient has clinical evidence of disease or condition expected to compromise survival or ability to complete follow-up assessments during the study duration 9. Patients currently participating in, or planning to enroll in another clinical study that may impact participation or outcomes of this clinical study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

kidney cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney cancer Renal cell carcinoma

Contacts and locations

Locations

  • The Royal Wolverhampton NHS Trust

    Wolverhampton, WV10 0QP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.